Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment

ESMO Open

Volumn 2, Issue 3, 2017, Pages

  Martinelli, Erika ^a   Sforza, Vincenzo ^a   Cardone, Claudia ^a   Capasso, Anna ^b   Nappi, Anna ^c   Martini, Giulia ^a   Napolitano, Stefania ^a   Rachiglio, Anna Maria ^c   Normanno, Nicola ^c   Cappabianca, Salvatore ^a   Reginelli, Alfonso ^a   Bisceglie, Maurizio Di ^d   Latiano, Tiziana Pia ^e   Maiello, Evaristo ^e   Orditura, Michele ^a   Vita, Fernando De ^a   Morgillo, Floriana ^a   Ciardiello, Fortunato ^a   Troiani, Teresa ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d Clinical Oncology Unit   (Italy)

^e CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

biomarkers; epithelial mesenchymal transition; Her 2; long responders; metastatic colorectal cancer; regorafenib

Indexed keywords

EID: 85049521445     PISSN: None     EISSN: 20597029     Source Type: Journal    
DOI: 10.1136/esmoopen-2017-000177     Document Type: Article

References (12)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA: A Cancer Journal for Clinicians 2016;66:7-30.
2. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal Cancer. Ann Oncol 2016;27:1386-422.
3. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011;129:245-55.
4. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal Cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:303-12.
5. Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015;16:619-29.
6. Van Cutsem E, Ciardiello F, Seitz J F, et al. Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer [abstract]. Ann Oncol 2015.
7. Giampieri R, Salvatore L, Del Prete M, et al. Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal Cancer patients. Sci Rep 2016;6:25195.
8. Del Prete M, Giampieri R, Loupakis F, et al. Prognostic clinical factors in pretreated colorectal Cancer patients receiving regorafenib: implications for clinical management6:33982-92, 10.18632/. Oncotarget 2015;6:591.
9. Tabernero J, Lenz HJ, Siena S, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal Cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 2015;16:937-48.
10. McLellan B, Ciardiello F, Lacouture ME, et al. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol 2015;26:2017-26.
11. Martinelli E, Martini G, Cardone C, et alAXL is an oncotarget in human colorectal Cancer. Oncotarget 2015;6:23281-96.
12. Teufel M, Schwenke S, Seidel H, et al. Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal Cancer (mCRC) enrolled in the CORRECT trial. [abstr 3558]. J Clin Oncol 2015.